Search | Clinical Trials Finder

Conditions: Glaucoma, Open-Angle, Ocular Hypertension
Interventions: AGN-207281 ophthalmic solutions (0.1% and 0.3%); AGN-207281 vehicle ophthalmic solution (placebo), timolol ophthalmic solution 0.5%, AGN-207281 vehicle ophthalmic solution (Placebo); Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 1
States / cities: Newport Beach, California

Conditions: Peripheral Artery Disease
Interventions: Fitbit Physical Activity Monitor, mHealth Glucometer, mHealth Blood Pressure; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Cystic Fibrosis, COPD, PCD - Primary Ciliary Dyskinesia, Covid19, Sinusitis, ILD, Normal Controls
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 14 Years and older
Enrollment: 160 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Renal Transplant Rejection
Interventions: Rituximab, No Rituximab; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 65 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2010
U.S. locations: 2
States / cities: Birmingham, Alabama • San Francisco, California

Conditions: End Stage Renal Disease
Interventions: AAT-023 solution (Zuragen), Heparin; Device · Drug
Lead sponsor: Ash Access Technology; Industry
Eligibility: 18 Years and older
Enrollment: 415 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 22
States / cities: Bakersfield, California • Lynwood, California • Middlebury, Connecticut + 17 more

Conditions: Alopecia, Breast Cancer
Interventions: bimatoprost ophthalmic solution, placebo; Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2016
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Apnea of Prematurity, Retinopathy of Prematurity, Pain
Interventions: sucrose solution; Dietary Supplement
Lead sponsor: Weill Medical College of Cornell University; Other
Eligibility: 5 Weeks and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis
Interventions: azithromycin, placebo, Tobramycin solution for inhalation; Drug
Lead sponsor: Bonnie Ramsey; Other
Eligibility: 6 Months to 18 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 45
States / cities: Anchorage, Alaska • Tucson, Arizona • Little Rock, Arkansas + 40 more

Conditions: Healthy
Interventions: LY3074828, LY3074828, Auto-injector (AI), Prefilled syringe (PFS); Biological · Drug · Device
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Daytona Beach, Florida

Conditions: Unilateral Cataract Extraction, Congenital Cataract
Interventions: OMS302, Phenylephrine HCl; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 1 Day to 47 Months
Enrollment: 78 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 11
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 8 more

Conditions: Pulmonary Fibrosis, Pulmonary Hypertension
Interventions: Iloprost Inhalation Solution (Ventavis); Drug
Lead sponsor: Actelion; Industry
Eligibility: 40 Years to 85 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 17
States / cities: Birmingham, Alabama • Los Angeles, California • San Diego, California + 14 more

Conditions: Barrett's Esophagus
Interventions: Proflavine, high resolution imaging; Drug
Lead sponsor: Anandasabapathy, Sharmila, M.D.; Individual
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Open Wound, Wound Heal
Interventions: Micro/nanobubble (MNB) - Irrigation, 0.9% Normal Saline - Irrigation, Micro/nanobubble (MNB) - Negative Pressure Wound Therapy with Instillation (NPWTi), 0.9% Normal Saline - Negative Pressure Wound Therapy with Instillation (NPWTi); Drug · Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2027
U.S. locations: 1
States / cities: Orange, California

Conditions: Chronic Plaque Psoriasis
Interventions: LCD, calcipotriol; Drug
Lead sponsor: NeoStrata Company, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Chronic Obstructive Pulmonary Disease, Bronchitis, Emphysema
Interventions: Arformoterol tartrate inhalation solution, Arformoterol 25 ųg BID, Formoterol 12 ųg BID, Placebo; Drug
Lead sponsor: Sumitomo Pharma America, Inc.; Industry
Eligibility: 35 Years and older
Enrollment: 443 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 60
States / cities: Birmingham, Alabama • Jasper, Alabama • Mobile, Alabama + 56 more

Conditions: Allergic Conjunctivitis
Interventions: AC-170 0.24%, AC-170 0%; Drug
Lead sponsor: Aciex Therapeutics, Inc.; Industry
Eligibility: 10 Years and older
Enrollment: 91 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Candidiasis, Oral
Interventions: silver citrate complex and acemannan; Drug
Lead sponsor: CelaCare Technologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Dry Eye Disease (DED)
Interventions: 3% trehalose; Drug
Lead sponsor: Southern California College of Optometry at Marshall B. Ketchum University; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Fullerton, California

Conditions: Primary Open Angle Glaucoma, Ocular Hypertension
Interventions: DE-126 Ophthalmic Solution 0.002% QD, Timolol Maleate Ophthalmic Solution 0.5% BID; Drug
Lead sponsor: Santen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 323 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 41
States / cities: Chandler, Arizona • Phoenix, Arizona • Sun City, Arizona + 34 more

Conditions: Gastroparesis
Interventions: Not listed
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Laryngeal Neoplasms, Head and Neck Cancers, Larynx Cancer
Interventions: MRI scan; Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: Dry Eye Syndrome
Interventions: TOP1630 Ophthalmic Solution, Placebo to TOP1630 Ophthalmic Solution; Drug
Lead sponsor: ORA, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 69 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Andover, Massachusetts

Conditions: Presbyopia
Interventions: BRIMOCHOL™, BRIMOCHOL™ F, Carbachol; Drug
Lead sponsor: Visus Therapeutics; Other
Eligibility: 45 Years to 80 Years
Enrollment: 18 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 3
States / cities: Glendale, California • Newport Beach, California • Memphis, Tennessee

Conditions: Kidney Failure, Chronic, Catheter-Related Infections
Interventions: Neutrolin, Heparin; Drug
Lead sponsor: CorMedix Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 806 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 5
States / cities: Riverside, California • San Dimas, California • Miami Gardens, Florida + 2 more

Search by objective public record fields.

Safety and Pharmacodynamics Study of AGN-207281 Ophthalmic Solutions Compared With Timolol Ophthalmic Solution or Placebo in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Verizon mHealth Solution for Patients With Peripheral Artery Disease (PAD)

High Resolution Micro OCT Imaging

The Effect of Rituximab on the Development of Anti-Donor Antibodies

A Multi-Centered, Two-Arm, Randomized Study Comparing the Effects of AAT-023 (Zuragen) Solution, and Heparin on the Incidence of Catheter Related Blood Stream Infections in Tunneled Chronic Central Venous Catheters for Dialysis

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Use of Sucrose to Relieve Pain During Eye Exams in Infants

OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

A Study of Two Formulations of LY3074828 in Healthy Participants

A Randomized Study in Children Ages Birth Through Three Years Undergoing Unilateral Cataract Extraction With or Without Lens Replacement

Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis

Accuracy, Yield and Clinical Impact of a Low-Cost HRME in the Early Diagnosis of Esophageal Adenocarcinoma

Micro/Nanobubbles (MNBs) for Treatment of Acute and Chronic Wounds

LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis

Safety and Efficacy of Arformoterol Tartrate Inhalation Solution in Subjects With Chronic Obstructive Pulmonary Disease

A Multi-Center Study Evaluating the Onset and Duration of Action of AC-170 0.24% Compared to Vehicle in the Conjunctival Allergen Challenge (CAC)

CelAgace™ OraRinse Solution for Treatment of Candidiasis

The Effects of 3% Trehalose Ophthalmic Solution on Corneal Epithelial Barrier Function

Multicenter Study Assessing the Efficacy and Safety of DE-126 Ophthalmic Solution 0.002% Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension

Vagus Nerve Response in Gastroparesis Patients

MRI Laryngeal Imaging With a Surface Coil

Safety and Efficacy of TOP1630 for Dry Eye Syndrome

Safety and Efficacy Study of BRIMOCHOL™, BRIMOCHOL™ F, and Carbachol in Subjects With Emmetropic Phakic and Pseudophakic Presbyopia

Study Assessing Safety & Effectiveness of a Catheter Lock Solution in Dialysis Patients to Prevent Bloodstream Infection